カレントテラピー　30-9　サンプル page 17/28

このページは カレントテラピー　30-9　サンプル の電子ブックに掲載されている17ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
前立腺癌治療の観点17：517-522, 199926）Finney G, Haynes AM, Cross P, et al：Cross -sectional analysisof sexual function after prostate brachytherapy. Urology66：377 -381, 200527）Scardino PT, Kim ED：....

前立腺癌治療の観点17：517-522, 199926）Finney G, Haynes AM, Cross P, et al：Cross -sectional analysisof sexual function after prostate brachytherapy. Urology66：377 -381, 200527）Scardino PT, Kim ED：Rationale for and results of nervegrafting during radical prostatectomy. Urology 57：1016 -1019, 200128）Emara AM, Chadwick E, Nobes JP, et al：Long -term toxicityand quality of life up to 10 years after low -dose ratebrachytherapy for prostate cancer. BJU Int 109：994-1000,201229）Zelefsky MJ, Chan H, Hunt M, et al：Long-term outcome ofhigh dose intensity modulated radiation therapy for patientswith clinically localized prostate cancer. J Urol 176：1415 -1419, 200630）Namiki S, Saito S, Ishidoya S, et al：Adverse effect of radicalprostatectomy on nocturia and voiding frequency symptoms.Urology 66：147-151, 200531）Wei JT, Dunn RL, Sandler HM, et al：Comprehensive comparisonof health -related quality of life after contemporarytherapies for localized prostate cancer. J Clin Oncol 20：557 -566, 200232）Chen RC, Clark JA, Talcott JA：Individualizing quality-oflifeoutcomes reporting：how localized prostate cancer treatmentsaffect patients with different levels of baseline urinary,bowel, and sexual function. J Clin Oncol 27：3916-3922, 200933）Pardo Y, Guedea F, Aguilo F, et al：Quality-of-life impact ofprimary treatments for localized prostate cancer in patientswithout hormonal treatment. J Clin Oncol 28：4687-4696,201034）Namiki S, Terai A, Nakagawa H, et al：Intraoperative electrophysiologicalconfirmation of neurovascular bundle preservationduring radical prostatectomy：long-term assessmentof urinary and sexual function. Jpn J Clin Oncol 35：660-666,200535）Secin FP, Koppie TM, Scardino PT, et al：Bilateral cavernousnerve interposition grafting during radical retropubicprostatectomy：Memorial Sloan -Kettering Cancer Centerexperience. J Urol 177：664-668, 200736）Kuwata Y, Muneuchi G, Igawa HH, et al：Dissociation of sexualfunction and sexual bother following autologous suralnerve grafting during radical prostatectomy. Int J Urol 14：510 -514, 200737）Saito S, Namiki S, Numahata K, et al：Relevance of postcatheterremoval incontinence to postoperative urinary functionafter radical prostatectomy. Int J Urol 13：1191-1196, 200638）Namiki S, Saito S, Nakagawa H, et al：Impact of unilateralsural nerve graft on recovery of potency and continence followingradical prostatectomy：3 -year longitudinal study. JUrol 178：212 -216, 200739）Menon M, Kaul S, Bhandari A, et al：Potency followingrobotic radical prostatectomy：a questionnaire based analysisof outcomes after conventional nerve sparing and prostaticfascia sparing techniques. J Urol 174：2291-2296, 200540）Patel VR, Coelho RF, Chauhan S, et al：Continence, potencyand oncological outcomes after robotic -assisted radical prostatectomy：earlytrifecta results of a high -volume surgeon.BJU Int 106：696-702, 201041）Isbarn H, Boccon -Gibod L, Carroll PR, et al：Androgendeprivation therapy for the treatment of prostate cancer：consider both benefits and risks. Eur Urol 55：62 -75, 200942）Mizokami A, Ueno S, Fukagai T, et al：Global update ondefining and treating high -risk localized prostate cancerwith leuprorelin：an Asian perspective. BJU Int 99（Suppl1）：6-9, 200743）Akaza H：Future prospects for luteinizing hormone-releasinghormone analogues in prostate cancer treatment. Pharmacology85：110-120, 201044）Schroder FH, Hugosson J, Roobol MJ, et al；ERSPC Investigators：Prostate-cancermortality at 11 years of follow-up.N Engl J Med 366：981-990, 201245）Mohamed NE, Bovbjerg DH, Montgomery GH, et al：Pretreatmentdepressive symptoms and treatment modality predictpost -treatment disease -specific quality of life amongpatients with localized prostate cancer. Urol Oncol 2011（Epub ahead of print）46）Diefenbach MA, Dorsey J, Uzzo RG, et al：Decision -makingstrategies for patients with localized prostate cancer. SeminUrol Oncol 20：55-62, 200247）Gwede CK, Pow -Sang J, Seigne J, et al：Treatment decision-makingstrategies and influences in patients with localizedprostate carcinoma. Cancer 104：1381-1390, 200548）Anandadas CN, Clarke NW, Davidson SE, et al；North WestUro -oncology Group：Early prostate cancer - -which treatmentdo men prefer and why? BJU Int 107：1762-1768, 2011Current Therapy 2012 Vol.30 No.990133